The protective effect of a nasal corticosteroid (Avamys) on exercise induced airway obstruction in cold air. - YSCO

Stichting Pediatrisch Onderzoek Enschede0 个研究点开始时间: 2009年2月6日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Clinical history of allergic rhinitis and/or allergic asthma.
•- Age between 12 and 17 years.
•- Ability to perform reproducible lung function tests, i.e. coefficient of the predicted value variation in 3 of 5 consecutive measurements < 5%.
•- Maximal FEV1 greater than 70% of predicted value.
•- Clinically stable period at least 3 weeks before the study period.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Use of intranasal or systemic corticosteroids in the last 4 weeks prior to the study.
•- Use of antihistamines, cromoglycates, anticholinergics in two weeks prior to the study.
•- Use of long acting bronchodilators 24 hours before testing.
•- Use of short acting bronchodilators 8 hours before testing.
•- Use of systemic corticosteroids, antihistamines, cromoglycates, anticholinergics, during the study.
•- Other pulmonary or cardiac disorder.
•- Deviation of the FEV1 of more than 12 % from baseline spirometry and the FEV1 before subsequent exercise provocation challenges.
•- Signs of gastro-esophageal reflux.

发起方

Stichting Pediatrisch Onderzoek Enschede